Memantine Protects Hippocampal Neuronal Function in Murine Human Immunodeficiency Virus Type 1 Encephalitis

Overview

Journal J Neurosci

Specialty Neurology

Date 2004 Aug 13

PMID 15306653

Citations 43

Authors

Eric R Anderson

Howard E Gendelman

Huangui Xiong

Affiliations

Soon will be listed here.

Abstract

Memantine, a low-to-moderate-affinity NMDA receptor antagonist, can be used to treat cognitive impairment associated with Alzheimer's disease. However, its potential neuroprotective effects for human immunodeficiency virus type 1-associated (HIV-1-associated) dementia are less well appreciated. To this end we studied hippocampal synaptic function in a severe combined immunodeficient (SCID) mouse model of HIV-1 encephalitis (HIVE). Human monocyte-derived macrophages (MDMs) infected with HIV-1(ADA) were injected stereotactically into the caudate and putamen of SCID mice, generating HIVE. These brain subregions are among those most affected in humans. Impaired synaptic transmission and long-term potentiation (LTP) were detected in the CA1 region of hippocampal brain slices of HIVE mice. Memantine-treated HIVE mice showed significant improvements in synaptic function during frequency facilitation tests and LTP induced by high-frequency stimulation when compared with untreated animals. Immunocytochemical measures of neuronal antigens mirrored the neuronal physiological tests. These results demonstrate that memantine attenuates hippocampal synaptic impairment in murine HIVE and provide a rationale for its use in infected humans who experience cognitive decline.

Citing Articles

Alzheimer's disease-like perturbations in HIV-mediated neuronal dysfunctions: understanding mechanisms and developing therapeutic strategies.

Jha N, Sharma A, Jha S, Ojha S, Chellappan D, Gupta G Open Biol. 2020; 10(12):200286.

PMID: 33352062 PMC: 7776571. DOI: 10.1098/rsob.200286.

Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders.

Omeragic A, Kayode O, Hoque M, Bendayan R Fluids Barriers CNS. 2020; 17(1):42.

PMID: 32650790 PMC: 7350632. DOI: 10.1186/s12987-020-00204-5.

BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage Through an APP-Dependent Mechanism.

Stern A, Ghura S, Gannon P, Akay-Espinoza C, Phan J, Yee A J Neurosci. 2018; 38(18):4288-4300.

PMID: 29632166 PMC: 5932640. DOI: 10.1523/JNEUROSCI.1280-17.2018.

N-(Pivaloyloxy)alkoxy-carbonyl Prodrugs of the Glutamine Antagonist 6-Diazo-5-oxo-l-norleucine (DON) as a Potential Treatment for HIV Associated Neurocognitive Disorders.

Nedelcovych M, Tenora L, Kim B, Kelschenbach J, Chao W, Hadas E J Med Chem. 2017; 60(16):7186-7198.

PMID: 28759224 PMC: 5795620. DOI: 10.1021/acs.jmedchem.7b00966.

Human Immunodeficiency Virus Promotes Mitochondrial Toxicity.

Rozzi S, Avdoshina V, Fields J, Trejo M, Ton H, Ahern G Neurotox Res. 2017; 32(4):723-733.

PMID: 28695547 PMC: 5711529. DOI: 10.1007/s12640-017-9776-z.

References

Zink W, Zheng J, Persidsky Y, Poluektova L, Gendelman H . The neuropathogenesis of HIV-1 infection. FEMS Immunol Med Microbiol. 1999; 26(3-4):233-41. DOI: 10.1111/j.1574-695X.1999.tb01394.x. View

Sardar A, Hutson P, Reynolds G . Deficits of NMDA receptors and glutamate uptake sites in the frontal cortex in AIDS. Neuroreport. 2000; 10(17):3513-5. DOI: 10.1097/00001756-199911260-00009. View

Nath A, Haughey N, Jones M, Anderson C, Bell J, Geiger J . Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol. 2000; 47(2):186-94. View

Mattson M, Pedersen W, Duan W, Culmsee C, Camandola S . Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann N Y Acad Sci. 2000; 893:154-75. DOI: 10.1111/j.1749-6632.1999.tb07824.x. View

Ensoli F, Fiorelli V, De Cristofaro M, Muratori D, Novi A, Isgro A . Role of immune-derived diffusible mediators in AIDS-associated neurological disorders. Arch Immunol Ther Exp (Warsz). 2000; 48(4):259-66. View

Jain K . Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs. 2000; 9(6):1397-406. DOI: 10.1517/13543784.9.6.1397. View

Kaul M, Garden G, Lipton S . Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001; 410(6831):988-94. DOI: 10.1038/35073667. View

Jiang Z, Piggee C, Heyes M, Murphy C, Quearry B, Bauer M . Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages. J Neuroimmunol. 2001; 117(1-2):97-107. DOI: 10.1016/s0165-5728(01)00315-0. View

Zink W, Anderson E, Boyle J, Hock L, Rodriguez-Sierra J, Xiong H . Impaired spatial cognition and synaptic potentiation in a murine model of human immunodeficiency virus type 1 encephalitis. J Neurosci. 2002; 22(6):2096-105. PMC: 6758279. View

10.

Persidsky Y, Gendelman H . Murine models for human immunodeficiency virus type 1-associated dementia: the development of new treatment testing paradigms. J Neurovirol. 2002; 8 Suppl 2:49-52. DOI: 10.1080/13550280290167993. View

11.

Anderson E, Boyle J, Zink W, Persidsky Y, Gendelman H, Xiong H . Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis. Neuroscience. 2003; 118(2):359-69. DOI: 10.1016/s0306-4522(02)00925-9. View

12.

Buddle M, Eberhardt E, Ciminello L, Levin T, Wing R, DiPasquale K . Microtubule-associated protein 2 (MAP2) associates with the NMDA receptor and is spatially redistributed within rat hippocampal neurons after oxygen-glucose deprivation. Brain Res. 2003; 978(1-2):38-50. DOI: 10.1016/s0006-8993(03)02758-6. View

13.

Reinhart T . Chemokine induction by HIV-1: recruitment to the cause. Trends Immunol. 2003; 24(7):351-3. DOI: 10.1016/s1471-4906(03)00163-7. View

14.

Arundine M, Tymianski M . Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium. 2003; 34(4-5):325-37. DOI: 10.1016/s0143-4160(03)00141-6. View

15.

Latysheva N, Rayevsky K . Chronic neonatal N-methyl-D-aspartate receptor blockade induces learning deficits and transient hypoactivity in young rats. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27(5):787-94. DOI: 10.1016/S0278-5846(03)00110-6. View

16.

Keilhoff G, Wolf G . Memantine prevents quinolinic acid-induced hippocampal damage. Eur J Pharmacol. 1992; 219(3):451-4. DOI: 10.1016/0014-2999(92)90487-o. View

17.

Lipton S, Chen H . Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ. 2003; 11(1):18-20. DOI: 10.1038/sj.cdd.4401344. View

18.

Tariot P, Farlow M, Grossberg G, Graham S, McDonald S, Gergel I . Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004; 291(3):317-24. DOI: 10.1001/jama.291.3.317. View

19.

Lipton S . Memantine prevents HIV coat protein-induced neuronal injury in vitro. Neurology. 1992; 42(7):1403-5. DOI: 10.1212/wnl.42.7.1403. View

20.

Seif El Nasr M, Peruche B, Rossberg C, Mennel H, Krieglstein J . Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol. 1990; 185(1):19-24. DOI: 10.1016/0014-2999(90)90206-l. View